ClinicalTrials.gg
CompletedNCT07839845Updated Sep 25, 2026

AIDAVA G1 LDL-C Substudy Protocol

An observational study in Myocardial Infarction, sponsored by North Estonia Medical Centre. Completed at 1 site in Estonia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by North Estonia Medical Centre · Observational

How we know

Updated Sep 25, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
37
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Myocardial Infarction with a site in Estonia — 1 open to participants now, 3 under way, 2 of them phase 3. Myocardial Infarction · Estonia.

Started
2024
the only one that year
Observational
2 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
North Estonia Medical Centre

Among the 11 studies in Myocardial Infarction with a site in Estonia, this one is the only one that started in 2024, is one of 2 observational ones, and was the 11th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

1 of the 11 studies in Myocardial Infarction with a site in Estonia is open now. Recruiting first, the newest first:

A study can be open while its sites in Estonia have not opened yet or have stopped. Only those recruiting at a site in Estonia →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Myocardial Infarction with a site in Estonia, or all of them as a file.
02

Study summary

This retrospective substudy describes low-density lipoprotein cholesterol (LDL-C) changes and treatment-target attainment among patients with previous myocardial infarction who participated in the AIDAVA first-generation (G1) prototype evaluation in Estonia, Austria and the Netherlands. Existing study data and clinical records are analysed. The LDL-C research question was developed after the original evaluation was planned and was not its prespecified efficacy endpoint. No additional intervention, treatment assignment, visit or blood sampling is introduced by this substudy. Findings are exploratory and cannot establish a causal effect of AIDAVA participation.

Read the detailed description

AIDAVA developed an AI-assisted system for integrating, curating and reusing personal health data. The original evaluation addressed technical performance, usability and acceptance. Cardiovascular participants contributed existing clinical records and longitudinal data, including home blood-pressure measurements, with support from study nurses and data curators. The cardiovascular protocol also envisaged automatic SMART risk-score assessment.

This registration covers only the secondary LDL-C analysis of the G1 post-myocardial infarction cohort. It does not register the full AIDAVA project, breast-cancer evaluation or G2 prototype evaluation. The original evaluation was not registered. This summary was prepared after the LDL-C analysis and does not represent prospective specification of its hypotheses, outcomes or analysis methods.

03

Conditions studied

  • Myocardial Infarction

Keywords

  • LDL-C
04

Who can participate

The criteria were revised on the registry on Sep 25, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults from the AIDAVA G1 cardiovascular cohort at North Estonia Medical Centre, Tallinn; Medical University of Graz, Graz; and Maastricht University Medical Centre+, Maastricht, with a documented history of type 1 myocardial infarction and permission for the relevant secondary use of their data.

The source cohort comprised digitally active adults with available medical data, smartphone ownership/use, a confirmed symptomatic type 1 myocardial infarction and written informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participation in the AIDAVA G1 cardiovascular cohort
  • Available baseline and follow-up LDL-C measurements with ascertainable measurement dates.

Exclusion criteria

Exclusion Criteria:

  • Absence of the required paired baseline and follow-up LDL-C measurements
  • Missing patient consent
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
37 participants (actual)
Patient registry
No

Groups and cohorts

  • AIDAVA G1 post-myocardial infarction cohort.

    Previous participation in two-week G1 health-data curation and prototype testing with nurse/curator guidance, and home blood-pressure data collection. These activities occurred in the original evaluation; no exposure is assigned in this retrospective substudy.

06

What researchers measure

Primary outcomes

  1. Percentage of participants with LDL-C below 1.8 mmol/L at follow-up.

    Time frame: Day 365

  2. Percentage of participants with LDL-C below 1.4 mmol/L at follow-up.

    Time frame: Day 365

07

Study locations

1 site
  • North Estonia Medical Centre
    Tallinn, Estonia
08

References and documents

Related links

Individual participant data

Plan to share: No — As per the Ethics Committee approval

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Jun 2026, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Sep 24, 2026
StartActual
Jul 1, 2024
Primary completionActual
Jun 1, 2026
CompletionActual
Jul 1, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited, 1 added; 1 exclusion criterion edited, 1 added
What changed in the criteria
Inclusion criteria
  • AddedParticipation in the AIDAVA G1 cardiovascular cohort
  • EditedParticipation in the G1 cardiovascular cohort and availableAvailable baseline and follow-up LDL-C measurements with ascertainable measurement dates.
Exclusion criteria
  • EditedAbsence of the required paired baseline and follow-up LDL-C measurements.
  • AddedMissing patient consent
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Eligibility 1 inclusion criterion edited, 1 added; 1 exclusion criterion edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • AddedParticipation in the AIDAVA G1 cardiovascular cohort
    • EditedParticipation in the G1 cardiovascular cohort and availableAvailable baseline and follow-up LDL-C measurements with ascertainable measurement dates.
    Exclusion criteria
    • EditedAbsence of the required paired baseline and follow-up LDL-C measurements.
    • AddedMissing patient consent

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07839845
Lead sponsor
North Estonia Medical Centre
Collaborators
Maastricht University, Medical University of Graz
Responsible party
Sponsor
First posted
Sep 24, 2026
Start date
Jul 1, 2024
Primary completion
Jun 1, 2026
Completion
Jul 1, 2026
Last update
Sep 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion